Eizen Joshua M
SEC CIK 1949621 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | See Remarks | 206.6K | — | $65.9K | 10 | 2024-03-15 | 2026-07-08 |
Most active insiders at ANTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Readnour Robin Shane | Dir | — | $316.7K |
| 2 | Eizen Joshua M | See Remarks | — | $52.9K |
| 3 | FitzPatrick Margaret M | Dir | $11.6K | — |
| 4 | Chanda Sanjay | Chief Development Off | — | $9,311 |
| 5 | Day Lucy | CFO | — | $8,862 |
| 6 | Prior Stephen David | Chief Strategy Off | — | $7,363 |
| 7 | Williams Sarah Joanne | Principal Accounting Off | — | $3,025 |
| 8 | Trenor Cameron C. III | Chief Medical Off | — | — |
| 9 | Marks Gilbert Lynn | Dir | — | — |
| 10 | Martin Patricia A. | Dir | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-10 18:15 | 2026-07-08 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $4.17 | -5,945 | 206.6K | -3% | -$24.8K | |
| D | 2026-02-23 | 2026-02-20 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | A - Grant | $0.00 | +50.0K | 207.5K | +32% | $0 |
| M | 2026-01-07 | 2026-01-05+ | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $1.00 | -24.9K | 159.4K | -13% | -$24.9K |
| 2025-11-06 | 2025-11-04 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $1.14 | -2,819 | 177.4K | -2% | -$3,214 | |
| D | 2025-02-28 | 2025-02-26 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | A - Grant | $0.00 | +58.5K | 175.2K | +50% | $0 |
| 2025-01-07 | 2025-01-03 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $1.34 | -9,663 | 116.7K | -8% | -$12.9K | |
| D | 2024-11-05 | 2024-11-04 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | A - Grant | $0.00 | +31.5K | 126.3K | +33% | $0 |
| 2024-07-12 | 2024-07-10 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | CLO | A - Grant | $0.00 | +60.0K | 94.8K | +172% | $0 | |
| A | 2024-03-29 | 2024-03-15 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | CLO | A - Grant | $0.00 | +30.0K | 32.4K | +1,226% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | CLO | A - Grant | $0.00 | +30.0K | 32.4K | +1,226% | $0 |
Purchase Sale Sale after option exercise All abbreviations